SCHEMBL6185875

SCHEMBL6185875

[CH2]CCOc1ccc(-c2nnc(-c3ccccc3-c3ccccc3)o2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 15/20 0.57
NPC1 O15118 14/20 0.57
ALDH1A1 P00352 13/20 0.57
KDM4E B2RXH2 11/20 0.57
SMN1; SMN2 Q16637 11/20 0.57
HPGD P15428 10/20 0.57
TP53 P04637 7/20 0.57
LMNA P02545 3/20 0.52
MAPT P10636 8/20 0.48
HSD17B10 Q99714 6/20 0.48
TSHR P16473 5/20 0.48
CASP3 P42574 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48
GAA P10253 2/20 0.48
POLB P06746 1/20 0.47
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6207779 0.84 NPC1 (0.57) RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL14016567 0.83 ALDH1A1 (0.60) RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL5639718 0.82 LSS (0.62) RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL4336383 0.79 RAB9A (0.74) RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL12765574 0.75 RAB9A (0.76) RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL72837 0.75 LSS (0.56) RAB9ANPC1ALDH1A1
SCHEMBL6205204 0.75 QPCT (0.54) RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL12914232 0.75 RAB9A (0.65) RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL14016573 0.74 ALDH1A1 (0.55) RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL5102941 0.74 ALDH1A1 (0.55) RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1505968-A1 MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES ELI LILLY AND COMPANY (US) 2005-02-16 EP disclosed
WO-2003097047-A1 MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES ELI LILLY AND COMPANY (US) 2003-11-27 WO disclosed